High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.
Identifieur interne : 000308 ( Main/Exploration ); précédent : 000307; suivant : 000309High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.
Auteurs : Joseph J. Pariser [États-Unis] ; Olufenwa J. Famakinwa ; Shane M. Pearce ; Doreen E. ChungSource :
- Journal of endourology / Endourological Society [ 1557-900X ] ; 2014.
Descripteurs français
- KwdFr :
- Adulte d'âge moyen, Antigène spécifique de la prostate (analyse), Complications postopératoires, Humains, Hyperplasie de la prostate (), Hyperplasie de la prostate (physiopathologie), Infections urinaires (étiologie), Lasers à solide (usage thérapeutique), Marqueurs biologiques (analyse), Miction (physiologie), Mâle, Qualité de vie, Résection transuréthrale de prostate (), Résection transuréthrale de prostate (effets indésirables), Sujet âgé, Sécurité, Thulium (usage thérapeutique), Thérapie laser (), Thérapie laser (effets indésirables), Volatilisation, Études de cohortes.
- MESH :
- analyse : Antigène spécifique de la prostate, Marqueurs biologiques.
- effets indésirables : Résection transuréthrale de prostate, Thérapie laser.
- physiologie : Miction.
- physiopathologie : Hyperplasie de la prostate.
- usage thérapeutique : Lasers à solide, Thulium.
- étiologie : Infections urinaires.
- Adulte d'âge moyen, Complications postopératoires, Humains, Hyperplasie de la prostate, Mâle, Qualité de vie, Résection transuréthrale de prostate, Sujet âgé, Sécurité, Thérapie laser, Volatilisation, Études de cohortes.
English descriptors
- KwdEn :
- Aged, Biomarkers (analysis), Cohort Studies, Humans, Laser Therapy (adverse effects), Laser Therapy (methods), Lasers, Solid-State (therapeutic use), Male, Middle Aged, Postoperative Complications, Prostate-Specific Antigen (analysis), Prostatic Hyperplasia (physiopathology), Prostatic Hyperplasia (surgery), Quality of Life, Safety, Thulium (therapeutic use), Transurethral Resection of Prostate (adverse effects), Transurethral Resection of Prostate (methods), Urinary Tract Infections (etiology), Urination (physiology), Volatilization.
- MESH :
- chemical , analysis : Biomarkers, Prostate-Specific Antigen.
- adverse effects : Laser Therapy, Transurethral Resection of Prostate.
- etiology : Urinary Tract Infections.
- methods : Laser Therapy, Transurethral Resection of Prostate.
- physiology : Urination.
- physiopathology : Prostatic Hyperplasia.
- surgery : Prostatic Hyperplasia.
- therapeutic use : Lasers, Solid-State, Thulium.
- Aged, Cohort Studies, Humans, Male, Middle Aged, Postoperative Complications, Quality of Life, Safety, Volatilization.
Abstract
The thulium laser was introduced in 2005 for the treatment of benign prostatic hyperplasia (BPH). Enucleation studies from outside North America show comparable efficacy and lower morbidity to transurethral resection of the prostate. A few studies exist describing outcomes of vaporization, the most commonly used technique for urologists. We present our 3-month outcomes of thulium laser vaporization of the prostate (ThuVP).
DOI: 10.1089/end.2014.0336
PubMed: 24936718
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000165
- to stream PubMed, to step Curation: 000165
- to stream PubMed, to step Checkpoint: 000165
- to stream Ncbi, to step Merge: 000858
- to stream Ncbi, to step Curation: 000858
- to stream Ncbi, to step Checkpoint: 000858
- to stream Main, to step Merge: 000308
- to stream Main, to step Curation: 000308
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.</title>
<author><name sortKey="Pariser, Joseph J" sort="Pariser, Joseph J" uniqKey="Pariser J" first="Joseph J" last="Pariser">Joseph J. Pariser</name>
<affiliation wicri:level="2"><nlm:affiliation>1 Section of Urology, University of Chicago , Chicago, Illinois.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>1 Section of Urology, University of Chicago , Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Famakinwa, Olufenwa J" sort="Famakinwa, Olufenwa J" uniqKey="Famakinwa O" first="Olufenwa J" last="Famakinwa">Olufenwa J. Famakinwa</name>
</author>
<author><name sortKey="Pearce, Shane M" sort="Pearce, Shane M" uniqKey="Pearce S" first="Shane M" last="Pearce">Shane M. Pearce</name>
</author>
<author><name sortKey="Chung, Doreen E" sort="Chung, Doreen E" uniqKey="Chung D" first="Doreen E" last="Chung">Doreen E. Chung</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2014">2014</date>
<idno type="doi">10.1089/end.2014.0336</idno>
<idno type="RBID">pubmed:24936718</idno>
<idno type="pmid">24936718</idno>
<idno type="wicri:Area/PubMed/Corpus">000165</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000165</idno>
<idno type="wicri:Area/PubMed/Curation">000165</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000165</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000165</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000165</idno>
<idno type="wicri:Area/Ncbi/Merge">000858</idno>
<idno type="wicri:Area/Ncbi/Curation">000858</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000858</idno>
<idno type="wicri:Area/Main/Merge">000308</idno>
<idno type="wicri:Area/Main/Curation">000308</idno>
<idno type="wicri:Area/Main/Exploration">000308</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness.</title>
<author><name sortKey="Pariser, Joseph J" sort="Pariser, Joseph J" uniqKey="Pariser J" first="Joseph J" last="Pariser">Joseph J. Pariser</name>
<affiliation wicri:level="2"><nlm:affiliation>1 Section of Urology, University of Chicago , Chicago, Illinois.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
<wicri:cityArea>1 Section of Urology, University of Chicago , Chicago</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Famakinwa, Olufenwa J" sort="Famakinwa, Olufenwa J" uniqKey="Famakinwa O" first="Olufenwa J" last="Famakinwa">Olufenwa J. Famakinwa</name>
</author>
<author><name sortKey="Pearce, Shane M" sort="Pearce, Shane M" uniqKey="Pearce S" first="Shane M" last="Pearce">Shane M. Pearce</name>
</author>
<author><name sortKey="Chung, Doreen E" sort="Chung, Doreen E" uniqKey="Chung D" first="Doreen E" last="Chung">Doreen E. Chung</name>
</author>
</analytic>
<series><title level="j">Journal of endourology / Endourological Society</title>
<idno type="eISSN">1557-900X</idno>
<imprint><date when="2014" type="published">2014</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term>
<term>Biomarkers (analysis)</term>
<term>Cohort Studies</term>
<term>Humans</term>
<term>Laser Therapy (adverse effects)</term>
<term>Laser Therapy (methods)</term>
<term>Lasers, Solid-State (therapeutic use)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Postoperative Complications</term>
<term>Prostate-Specific Antigen (analysis)</term>
<term>Prostatic Hyperplasia (physiopathology)</term>
<term>Prostatic Hyperplasia (surgery)</term>
<term>Quality of Life</term>
<term>Safety</term>
<term>Thulium (therapeutic use)</term>
<term>Transurethral Resection of Prostate (adverse effects)</term>
<term>Transurethral Resection of Prostate (methods)</term>
<term>Urinary Tract Infections (etiology)</term>
<term>Urination (physiology)</term>
<term>Volatilization</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Antigène spécifique de la prostate (analyse)</term>
<term>Complications postopératoires</term>
<term>Humains</term>
<term>Hyperplasie de la prostate ()</term>
<term>Hyperplasie de la prostate (physiopathologie)</term>
<term>Infections urinaires (étiologie)</term>
<term>Lasers à solide (usage thérapeutique)</term>
<term>Marqueurs biologiques (analyse)</term>
<term>Miction (physiologie)</term>
<term>Mâle</term>
<term>Qualité de vie</term>
<term>Résection transuréthrale de prostate ()</term>
<term>Résection transuréthrale de prostate (effets indésirables)</term>
<term>Sujet âgé</term>
<term>Sécurité</term>
<term>Thulium (usage thérapeutique)</term>
<term>Thérapie laser ()</term>
<term>Thérapie laser (effets indésirables)</term>
<term>Volatilisation</term>
<term>Études de cohortes</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers</term>
<term>Prostate-Specific Antigen</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Laser Therapy</term>
<term>Transurethral Resection of Prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Antigène spécifique de la prostate</term>
<term>Marqueurs biologiques</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Résection transuréthrale de prostate</term>
<term>Thérapie laser</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Urinary Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Laser Therapy</term>
<term>Transurethral Resection of Prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Miction</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Urination</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathologie" xml:lang="fr"><term>Hyperplasie de la prostate</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Prostatic Hyperplasia</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en"><term>Prostatic Hyperplasia</term>
</keywords>
<keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Lasers, Solid-State</term>
<term>Thulium</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Lasers à solide</term>
<term>Thulium</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Infections urinaires</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Cohort Studies</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Postoperative Complications</term>
<term>Quality of Life</term>
<term>Safety</term>
<term>Volatilization</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Complications postopératoires</term>
<term>Humains</term>
<term>Hyperplasie de la prostate</term>
<term>Mâle</term>
<term>Qualité de vie</term>
<term>Résection transuréthrale de prostate</term>
<term>Sujet âgé</term>
<term>Sécurité</term>
<term>Thérapie laser</term>
<term>Volatilisation</term>
<term>Études de cohortes</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The thulium laser was introduced in 2005 for the treatment of benign prostatic hyperplasia (BPH). Enucleation studies from outside North America show comparable efficacy and lower morbidity to transurethral resection of the prostate. A few studies exist describing outcomes of vaporization, the most commonly used technique for urologists. We present our 3-month outcomes of thulium laser vaporization of the prostate (ThuVP).</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Illinois</li>
</region>
</list>
<tree><noCountry><name sortKey="Chung, Doreen E" sort="Chung, Doreen E" uniqKey="Chung D" first="Doreen E" last="Chung">Doreen E. Chung</name>
<name sortKey="Famakinwa, Olufenwa J" sort="Famakinwa, Olufenwa J" uniqKey="Famakinwa O" first="Olufenwa J" last="Famakinwa">Olufenwa J. Famakinwa</name>
<name sortKey="Pearce, Shane M" sort="Pearce, Shane M" uniqKey="Pearce S" first="Shane M" last="Pearce">Shane M. Pearce</name>
</noCountry>
<country name="États-Unis"><region name="Illinois"><name sortKey="Pariser, Joseph J" sort="Pariser, Joseph J" uniqKey="Pariser J" first="Joseph J" last="Pariser">Joseph J. Pariser</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000308 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000308 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Terre |area= ThuliumV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:24936718 |texte= High-power thulium laser vaporization of the prostate: short-term outcomes of safety and effectiveness. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:24936718" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a ThuliumV1
![]() | This area was generated with Dilib version V0.6.21. | ![]() |